News | Atrial Fibrillation | May 15, 2018

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk

HRS late-breaking study authors say further investigation is needed to understand the temporal relationship of marijuana and arrhythmias

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular fibrillation (VF) and ventricular tachycardia (VT) following an acute myocardial infarction (AMI). The study also reported that marijuana users had a decreased risk of atrial fibrillation (AFib) and in-hospital mortality. The results of the study were presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

Recent federal data reported a stunning 455 percent increase in marijuana consumption among U.S. adults ages 55-64 years and 333 percent in ages over 64 years between 2002 and 2014 [1]. In fact, one in eight Americans say they smoke marijuana [2]. While results of previous studies show links between cannabis use and increases in heart rate and blood pressure, little is known about the cardiac-related effects for heart arrhythmias including VF and VT.  

The study compared clinical profiles and in-hospital outcomes between reported marijuana users vs. non-users from 1994 to 2013. The primary endpoint was VT/VF or cardiac arrest and the secondary endpoint was atrial fibrillation or mortality. The patient group included people between the ages of 18-70 years with a primary diagnosis of AMI (ICD-9-CM code 410.xx) from eight states including California, New York, New Jersey, Vermont, New Hampshire, Colorado, Texas and West Virginia. Patients who used cocaine, methamphetamine or alcohol were excluded from the study. Variables included in a step-forward multivariate logistic regression model included age, race and cardiac risk factors. 

In total, 3,854 of 1,273,897 patients admitted with AMI reported marijuana use. Findings from the study show marijuana users tended to be younger, male and less likely to have coronary artery disease (CAD) or coronary risk factors than non-users. Primary endpoints show that 9.7 percent (n=374) marijuana users and 9.7 percent (n=122,797) non-users experienced VT/VF or cardiac arrest. Secondary endpoints show that 4.5 percent (n=173) marijuana users vs. 8.7 percent (n=110,153) non-users had AFib, and 4 percent (n=135) vs. 6 percent (n=75,311) died, respectively. Despite there being no difference in the risk for VT/VF, researchers found in-hospital mortality was lower in marijuana users and a trend toward decreased risk of AFib was lower in marijuana users. 

"The legalization of marijuana is spreading quickly across the U.S. resulting in more people using it, but we still don’t know the true, long-term impact it has on one’s heart health. Our study is the first to examine the relationship between marijuana use after a heart attack and various arrhythmias and we did not see a negative connection," said senior author Christine Tompkins, M.D., assistant professor of cardiology medicine at University of Colorado School of Medicine. "We are just one step closer to a better understanding of the various heart effects of marijuana, so that we are able to take the necessary actions to provide optimal patient care." 

The authors have noted that future studies are warranted to further understand the temporal relationship of marijuana and arrhythmias in patients with chronic ischemic heart disease, and are actively involved in a prospective observational study. They have also expressed interest in understanding the effects of marijuana in other chronic cardiac conditions, such as congestive heart failure and hypertension. The authors emphasize a need to understand how marijuana affects the heart so as to provide patients with informed choices, particularly since use in adults over the age of 50 years is increasing exponentially.  

Heart Rhythm 2018 is the most comprehensive educational program for heart rhythm professionals, featuring more than 200 educational sessions and more than 140 exhibitors showcasing innovative products and services. For more information: www.hrssessions.org

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

References: 

1. Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill Summ 2016;65 (No. SS-11):1–25. DOI: http://dx.doi.org/10.15585/mmwr.ss6511a1.

2. Gallup, Inc. "In U.S., 45% Say They Have Tried Marijuana." Gallup.com,  19 July 2017, news.gallup.com/poll/214250/say-tried-marijuana.aspx.  

 

#HRS2018 #HRS18

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...
Overlay Init